Theratechnologies Inc. (NASDAQ:THTX) Short Interest Down 44.0% in November

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 43,800 shares, a decrease of 44.0% from the November 15th total of 78,200 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average trading volume of 48,900 shares, the days-to-cover ratio is currently 0.9 days.

Theratechnologies Stock Up 7.0 %

Shares of NASDAQ:THTX traded up $0.10 during midday trading on Friday, reaching $1.52. The company had a trading volume of 101,552 shares, compared to its average volume of 46,684. Theratechnologies has a 1-year low of $1.08 and a 1-year high of $2.58. The stock has a market cap of $69.89 million, a PE ratio of -15.20 and a beta of 1.42. The business’s 50 day moving average price is $1.28 and its 200 day moving average price is $1.31.

Theratechnologies (NASDAQ:THTX) last released its earnings results on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The firm had revenue of $22.60 million during the quarter. During the same period in the previous year, the company earned ($0.03) earnings per share. On average, research analysts expect that Theratechnologies will post 0.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Theratechnologies

An institutional investor recently raised its position in Theratechnologies stock. Cyndeo Wealth Partners LLC raised its position in shares of Theratechnologies Inc. (NASDAQ:THTX) by 26.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,311 shares of the company’s stock after acquiring an additional 27,191 shares during the period. Cyndeo Wealth Partners LLC owned approximately 0.29% of Theratechnologies worth $163,000 at the end of the most recent quarter.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.